INFO & CONTACTS:  +39 02 2390 1

JA PCM – Joint Action Personalised Cancer

JA PCM

Funding Organization: European Union (EU4Health Programme 2021–2027)

Principal Investigator: Prof. Pruneri Giancarlo

Start date:

End date:

Main Facility: Anatomia Patologica 1

This project is funded by the European Union (grant number 101233450). Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HaDEA. Neither the European Union nor the granting authority can be held responsible for them.

Personalised cancer medicine (PCM) tailors cancer treatment to each individual’s unique profile, including their medical history, genomics, and lifestyle. This approach is becoming increasingly important in the cancer care continuum, from prevention, diagnosis, treatment, and follow-up. 

The European Joint Action on Personalised Cancer Medicine (JA PCM) brings together 29 European countries and 145 partner organisations to advance personalised cancer care across Europe. The project aims to create a sustainable cross-border network to foster innovation, good practise, equity, and collaboration in personalised cancer care. The project is co-funded by the European Commission and has an overall budget of €31.6 million. 

The Joint Action will focus on three ‘arms’, representing the patient pathway: 

  1. personalised prevention and early detection;
  2. personalised medicine; and
  3. personalised follow-up and tertiary prevention

Each arm consists of two technical work packages and is supported by at least one dedicated pilot application. In addition, two transversal pilots cover all arms. The pilots will cover seven themes:

1.         Pathway, access and implementation of risk-informed cancer prevention across Europe.

  • Developing and testing care pathways that adapt cancer prevention strategies to individual risk profiles 

2.         Implementation readiness for polygenic risk scores in screening 

  • Exploring how genetic information can help better estimate cancer risk and inform prevention. 

3.         Supranational molecular tumour board for complex cases/countries without MTB

  • Strengthening the use of molecular data to support clinical decision-making in multidisciplinary tumour board meetings 

4.         Continuous data collection via a federated sharing platform

  • Developing ways to securely collect and analyse real-world cancer data from multiple countries, in order to build larger patient cohorts and generate evidence that can inform decisions on cancer treatments and improve patient outcomes. 

5.         Digital tools for remote monitoring, needs assessment, self-management, and supportive care

  • Developing and testing digital tools to support the remote monitoring of patients’ health status. 

6.         Personalised management of cancer predisposition across the patient journey (CPS Compass)

  • Integrating information on genetic predisposition into different stages of the patient journey, from screening to follow-up. 

7.         Implementation of ctDNA guided decision-making across the patient journey (LB-ctDNA)

  • Assessing the use of blood-based tests to detect, monitor, or follow cancer in a less invasive way. 

The activities of the project will be supported by transversal activities, including external quality assessments for liquid biopsy, education and training initiatives, work on the ethical, legal and social implications of PCM; and a health technology and data assessment.

JA PCM will accelerate cross-border collaboration, strengthen European knowledge networks, and create synergies with EU initiatives to promote equitable access to personalised cancer medicine across Europe. Over the next four years, the initiative will lay the foundations for a sustainable, measurable and patient-centred European framework for personalised oncology.

Coordinator: Sciensano (SC)

Number of partners: 145

Total Project cost: € 31 601 131.13

EU Contribution: € 25 280 904.88

Project number: 101233450

Participant countries: Belgium, Bosnia and Herzegovina, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Slovenia, Spain, Sweden, Ukraine, Moldova, Romania

Principal Investigator Prof. Pruneri Giancarlo

Struttura Principale: Pathological Anatomy 1
Complex Structure

Last update: 07/05/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe